Image pharmaphorum Editor Views & Analysis Deep Dive: Market Access It’s fair to say this is the most interesting time ever for market access. White Papers Sponsored A digital health roadmap for pharma, medical devices and ins... COVID-19 has massively accelerated the uptake of digital health technology across the whole ecosystem, with important implications for pharma, medical device and insurance tech companies. Views & Analysis Designing HCP engagement for the next normal Life sciences companies’ engagement with HCPs has changed significantly in the past 12 months, as the COVID-19 pandemic struck. Views & Analysis Global impact: How regulatory affairs is shaping development... When it comes to developing cutting-edge innovations, Astellas aims to be at the forefront. Load more results
Views & Analysis Deep Dive: Market Access It’s fair to say this is the most interesting time ever for market access.
White Papers Sponsored A digital health roadmap for pharma, medical devices and ins... COVID-19 has massively accelerated the uptake of digital health technology across the whole ecosystem, with important implications for pharma, medical device and insurance tech companies.
Views & Analysis Designing HCP engagement for the next normal Life sciences companies’ engagement with HCPs has changed significantly in the past 12 months, as the COVID-19 pandemic struck.
Views & Analysis Global impact: How regulatory affairs is shaping development... When it comes to developing cutting-edge innovations, Astellas aims to be at the forefront.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.